The maverick practice of off-label prescribing - giving drugs for unapproved conditions/patients - is once again in the limelight. The US Food and Drug Administration (FDA) has issued a warning against using ‘atypical antipsychotics’ to treat...
Drug companies have been accused of suppressing vital data showing that their new-generation atypical antipsychotics are killing around one in four elderly dementia patients. The startling discovery was made in nine separate studies that were...
The so-called ‘atypical antipsychotic drugs’ have been hailed as a pharmaceutical breakthrough and have, by now, largely replaced the old guard of neuroleptics. However, a recent overview of these modern medicines questions the claim that this new...
Psychiatric patients, especially those under 40, are at high risk of developing cardiovascular disease and diabetes. Schizophrenics are two to three times more likely to die of heart disease than the rest of us (Diabetes Care, 2003; 26: 1597-605).